NCCN Guidelines Insights: Rectal Cancer, Version 6.2020
Al B. Benson, Alan Paul Venook, Mahmoud M. Al-Hawary et al. · Journal of the National Comprehensive Cancer Network · 2020
The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines. These updates include clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer, with a focus on new treatment options for patients with BRAF V600E- or HER2 amplification-positive disease.
Cited by 484 works. doi:10.6004/jnccn.2020.0032 Open-access PDF
Authors
- Al B. Benson
- Alan Paul Venook
- Mahmoud M. Al-Hawary
- Mustafa A. Arain
- Yi‐Jen Chen
- Kristen Keon Ciombor
- Stacey A. Cohen
- Harry S. Cooper
- Dustin A. Deming
- Ignacio Garrido‐Laguna
- Jean L. Grem
- Andrew John Gunn
- Sarah E. Hoffe
- Joleen Marie Hubbard
- Steven R. Hunt
- Natalie N. Kirilcuk
- Smitha Krishnamurthi
- Wells A. Messersmith
- Jeffrey A. Meyerhardt
- Eric David Miller
References
- Cancer statistics, 2020
- Cancer statistics, 2011
- Colorectal cancer statistics, 2020
- Guidelines 2000 for Colon and Rectal Cancer Surgery
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- Patterns of pelvic recurrence following definitive resections of rectal cancer
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials